Your session is about to expire
← Back to Search
Beta Blocker
Timolol Option for Ulcerated Hemangiomas (TOUCH Trial) (TOUCH Trial)
Phase 2
Waitlist Available
Led By Vikash S. Oza, MD
Research Sponsored by Children's Hospital of Philadelphia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 3 months
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group
Summary
The purpose of this study is to determine whether Timolol 0.5% Gel Forming Solution is safe and effective in promoting wound healing of infantile ulcerated hemangiomas compared with standard conservative management with topical antibiotic.
Eligible Conditions
- Infantile Hemangiomas
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 3 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Evaluate number of participants with changes in Glucose levels after drug is applied
Evaluate number of participants with changes in Heart Rate after drug is applied
Body Weight Changes
+4 moreAwards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Timolol 0.5% Gel Forming Solution (GFS)Experimental Treatment1 Intervention
Half of enrolled subjects will receive topical Timolol
Group II: Mupirocin 2% ointmentActive Control1 Intervention
Half of enrolled subjects will receive Mupirocin
Find a Location
Who is running the clinical trial?
Children's Hospital of PhiladelphiaLead Sponsor
731 Previous Clinical Trials
8,473,040 Total Patients Enrolled
Society for Pediatric DermatologyOTHER
8 Previous Clinical Trials
490 Total Patients Enrolled
1 Trials studying Infantile Hemangiomas
118 Patients Enrolled for Infantile Hemangiomas
Vikash S. Oza, MDPrincipal InvestigatorChildren's Hospital of Philadelphia, Attending Physician
Patrick McMahon, MDPrincipal InvestigatorChildren's Hospital of Philadelphia
1 Previous Clinical Trials
40 Total Patients Enrolled
Albert C. Yan, MDPrincipal InvestigatorChildren's Hospital of Philadelphia, Chair of Pediatric Dermatology